Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 9;13(1):150.
doi: 10.1186/s13045-020-00980-5.

Emerging agents and regimens for multiple myeloma

Yang Yang  1 , Yi Li  1 , Huiyao Gu  1 , Mengmeng Dong  1 , Zhen Cai  2   3   4
Affiliations
Review

Emerging agents and regimens for multiple myeloma

Yang Yang et al. J Hematol Oncol. .

Abstract

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody-drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.

Keywords: BiTE; CAR-T; Checkpoint inhibitor; Immunotherapy; Monoclonal antibody; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Therapeutic options for targeting myeloma
See this image and copyright information in PMC

References

    1. Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136. doi: 10.1186/s13045-019-0807-5. - DOI - PMC - PubMed
    1. Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–65. doi: 10.1002/hon.2586. - DOI - PMC - PubMed
    1. Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Blade J, Boccadoro M, et al. Insights on multiple myeloma treatment strategies. Hemasphere. 2019;3(1):e163. doi: 10.1097/HS9.0000000000000163. - DOI - PMC - PubMed
    1. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527. doi: 10.1016/S0140-6736(16)31594-X. - DOI - PMC - PubMed
    1. Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337–1345. doi: 10.1182/blood.2019000241. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances